HL SELECT GLOBAL GROWTH SHARES

New Holding – Phreesia

Fund changes

Important information - The value of this fund can still fall so you could get back less than you invested, especially over the short term. The information shown is not personal advice and the information about individual companies represents our view as managers of the fund. It is not a personal recommendation to invest in a particular company. If you are at all unsure of the suitability of an investment for your circumstances please contact us for personal advice. The HL Select Funds are managed by our sister company HL Fund Managers Ltd.

Gareth Campbell - Fund Manager

5 October 2020

New Holding – Phreesia

Phreesia is a healthcare IT business which improves the operational efficiency of care providers and delivers a better experience to patients.

Its main product is a patient intake software which automates many stages of the process which are traditionally completed manually using pen and paper. The second largest business is a payment processing solution which enables the collection of patient’s payments. Its life sciences business delivers targeted advertisements and surveys to patients on the behalf of pharmaceutical companies.

Healthcare IT benefits from long term trends

Phreesia are a beneficiary of some of the strongest secular trends in US healthcare, we believe this should support high industry growth rates for the foreseeable future.

The US healthcare systems is shifting to a value-based care model, increasing the focus on the quality of outcomes over the quantity of care billed. Phreesia enables this by collecting clinical outcome data and patient surveys to give immediate feedback to providers.

As US consumers are increasingly responsible for a higher percentage of their healthcare costs, they have a growing influence over who they choose to provide care and have higher expectations of service quality, this has led to a growing trend of consumerism within US healthcare. Phreesia offer a higher quality service, a simplified payment process and deliver an overall better experience to patients.

US healthcare spending is at unsustainable levels at 17% of GDP compared to a peer average of 10% and according to leading academics around 25% of the budget is wasted. Phreesia have many tools that can improve efficiency and highlight areas of waste. Alongside other healthcare IT providers they are part of the solution so are likely to maintain high growth rates despite potential headwinds to overall healthcare spending.

Why Phreesia?

Phreesia estimate its addressable market at $7 billion, with only $120 million of revenue this year it could continue to grow revenue over 20% annually for the foreseeable future. Its main competition is legacy manual and paper-based systems with a recent survey suggesting less than 30% of solutions are digital.

As a software platform Phreesia can add additional products and services, increasing their value to customers enabling them to increase its average selling price. Currently the basic package Phreesia offer costs around $150 per month, but if you subscribed to all their additional services this would increase to $400 per month.

Software businesses have low marginal costs for supplying additional copies of software, this means they typically have strong operating leverage. This combined with high gross margins currently means we believe Phreesia will generate significant amounts of cash at maturity, despite the low levels of profitability today.

The coronavirus has caused a reduction in patient procedures which has impacted Phreesia’s payment processing revenue causing the business to underperform many of its peers. The core patient software business continues to grow revenue over 20%, with 80% of customers adding payment processing and as the impact of COVID declines patient procedures will increase. For these reasons we think the long-term growth of the business is unchanged and we see this as an opportunity to own a high-quality business with exceptional long-term growth potential.

Barriers to entry

Phreesia are the largest and highest regarded patient intake software business, shown by the fact that it retains over 90% of its customers year after year. Additionally, its investments in R&D and focus on innovation mean that the hurdle to compete against them is constantly rising.

Phreesia’s customer base is highly fragmented with 69% being independent physician groups. Phreesia’s uniqueness is that they are a subscription software business which has standardised integration with all the major healthcare IT providers, this enables them to sell to this market profitably despite the low revenue per provider.

A combination of culture and expertise means that few of Phreesia’s competitors are well positioned to directly compete with it. The largest healthcare IT companies are focused on improving the efficiency of healthcare treatment for sophisticated users such as doctors, they have no expertise in improving the patient or administrator’s user experience. While payment and software peers tend to lack the specialist healthcare knowledge required to succeed.

What we sold to buy Phreesia

After strong performance from many of our technology and healthcare businesses we trimmed some of these positions and that cash was used to add Phreesia to the portfolio.

Important - This article is not advice or a recommendation to buy, sell or hold any investment. No view is given on the present or future value or price of any investment, and investors should form their own view on any proposed investment. This article has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is considered a marketing communication. Non-independent research is not subject to FCA rules prohibiting dealing ahead of research, however HL has put controls in place (including dealing restrictions, physical and information barriers) to manage potential conflicts of interest presented by such dealing. Please see our full non-independent research

Non-Independent Research Disclosure

The information on this website is not intended to be advice or a recommendation to buy, sell or hold any investment mentioned. No view is given as to the present or future value or price of any investment, and investors should form their own view in relation to any proposed investment.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.

The research material provided on our website is not an offer to buy or sell any of the stocks mentioned. Hargreaves Lansdown accepts no responsibility for any use made of these comments and for any consequences that may result. We cannot guarantee the accuracy or completeness of the information provided and consideration has not been given to the personal circumstances of any investor. Therefore any person acting on it does so entirely at their own risk and must assess the suitability of any investment for their own personal circumstances and individual investment objectives. It is not a personal recommendation.

Although we are not specifically constrained from dealing ahead of any research material we do not seek to take advantage of it before it is provided to our clients. We aim to establish and maintain and operate effective organisational and administrative arrangements with a view to taking all reasonable steps to prevent conflicts of interest from constituting or giving rise to a material risk of damage to the interests of our clients (including restrictions on dealing for writers of equity commentary).

Hargreaves Lansdown Fund Managers Ltd (HLFM) manages funds that may hold investments which are the subject of commentary prepared and published by other parts of the Hargreaves Lansdown group. Accordingly, appropriate organisational and administrative controls (including physical and information barriers, known as “Chinese Walls”) are in place between different parts of our business, including our marketing and fund management functions, in order to manage these potential conflicts of interest. For more information please see our Conflicts of Interest policy. HLFM currently manages three funds which hold individual equity securities. Details of the significant shareholdings held by these funds can be found here for the HL Select UK Growth Shares fund, here for the HL Select UK Income Shares fund and here for the HL Select Global Growth Shares fund. Hargreaves Lansdown (Nominees) Limited holds individual securities as nominee on behalf of underlying clients of Hargreaves Lansdown, and does not exercise control over or hold the beneficial ownership of these securities.

We do not intend to provide recommendations to buy, sell or hold particular investments, nor do we provide price targets. Our opinions on particular investments (and the facts underlying them) are valid as at the date of publication, but can change at any time, and we may not update our views on any particular investment on a regular basis. Accordingly such opinions and facts may become outdated or obsolete after the date of publication.

Issued by Hargreaves Lansdown Asset Management Limited, which is authorised and regulated by the Financial Conduct Authority (FCA Register number 115248, see FCA register for registration details) and registered in England and Wales No 1896481. Registered office: 1 College Square South, Anchor Road, Bristol BS1 5HL.

for more information. Unless otherwise stated performance figures are from Bloomberg and estimates, including prospective yields, are a consensus of analyst forecasts from Bloomberg. They are not a reliable indicator of future performance. Yields are variable and not guaranteed.